Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Multiple Myeloma

4 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCHEM1377

03/14/2014

A Phase 1 Study of Arry-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Treatment

VICCHEM1392

03/12/2014

A Phase 1, Open-label, Dose-Escalation Study of the Safety of SNX-5422 Mesylate in Subjects with Refractory Hematological Malignancies

Treatment

VICCHEM12107

03/31/2013

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

Treatment

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers